Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia
Stopped early · Phase 3 · Has a placebo group
Conditions studied: Schizophrenia
In brief
This primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.
Key facts
- Study ID
- NCT05654870
- Run by
- Neurocrine Biosciences
- People needed
- 8
- Starts
- 2023-01-05
- Expected to finish
- 2023-11-08
- Last updated by the study team
- 2024-11-12
Who can join
Age: 13 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Neurocrine Clinical Site — San Jose, California, United States
- Neurocrine Clinical Site — Coral Gables, Florida, United States
- Neurocrine Clinical Site — Atlanta, Georgia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.